| pubmed-article:15087031 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15087031 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15087031 | lifeskim:mentions | umls-concept:C0001688 | lld:lifeskim |
| pubmed-article:15087031 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15087031 | lifeskim:mentions | umls-concept:C0023473 | lld:lifeskim |
| pubmed-article:15087031 | lifeskim:mentions | umls-concept:C0879626 | lld:lifeskim |
| pubmed-article:15087031 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:15087031 | lifeskim:mentions | umls-concept:C0906802 | lld:lifeskim |
| pubmed-article:15087031 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:15087031 | pubmed:dateCreated | 2004-4-16 | lld:pubmed |
| pubmed-article:15087031 | pubmed:abstractText | The aberrant regulation of the protein tyrosine kinase (PTK) activity of P210(BCR-ABL), which is the protein product of Bcr-Abl fusion gene leads to the pathogenesis of chronic myeloid leukemia (CML). Though STI571 can inhibit specifically the PTK activity of P210(Bcr-Abl) and greatly improve the clinic curative effect on CML in chronic phase, its effect on CML in accelerated phase and blast crisis is not clear. In this article, we attempted to analyze the clinic efficacy and side effect of STI571 treatment on CML patients in different phase. In addition, we analyzed the potential mechanism of STI571 resistance in accelerated/blast crisis CML with genetic methods. | lld:pubmed |
| pubmed-article:15087031 | pubmed:language | chi | lld:pubmed |
| pubmed-article:15087031 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15087031 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15087031 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15087031 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15087031 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15087031 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15087031 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:15087031 | pubmed:issn | 1000-467X | lld:pubmed |
| pubmed-article:15087031 | pubmed:author | pubmed-author:ZhangSongS | lld:pubmed |
| pubmed-article:15087031 | pubmed:author | pubmed-author:XuBingB | lld:pubmed |
| pubmed-article:15087031 | pubmed:author | pubmed-author:LiuXiao-LiXL | lld:pubmed |
| pubmed-article:15087031 | pubmed:author | pubmed-author:ZhouShu-YunSY | lld:pubmed |
| pubmed-article:15087031 | pubmed:author | pubmed-author:DuQing-FengQF | lld:pubmed |
| pubmed-article:15087031 | pubmed:author | pubmed-author:LiuQi-FaQF | lld:pubmed |
| pubmed-article:15087031 | pubmed:author | pubmed-author:MengFan-YiFY | lld:pubmed |
| pubmed-article:15087031 | pubmed:author | pubmed-author:SongLan-LinLL | lld:pubmed |
| pubmed-article:15087031 | pubmed:author | pubmed-author:ZhengWei-Yang... | lld:pubmed |
| pubmed-article:15087031 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15087031 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:15087031 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15087031 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15087031 | pubmed:pagination | 421-5 | lld:pubmed |
| pubmed-article:15087031 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:15087031 | pubmed:meshHeading | pubmed-meshheading:15087031... | lld:pubmed |
| pubmed-article:15087031 | pubmed:meshHeading | pubmed-meshheading:15087031... | lld:pubmed |
| pubmed-article:15087031 | pubmed:meshHeading | pubmed-meshheading:15087031... | lld:pubmed |
| pubmed-article:15087031 | pubmed:meshHeading | pubmed-meshheading:15087031... | lld:pubmed |
| pubmed-article:15087031 | pubmed:meshHeading | pubmed-meshheading:15087031... | lld:pubmed |
| pubmed-article:15087031 | pubmed:meshHeading | pubmed-meshheading:15087031... | lld:pubmed |
| pubmed-article:15087031 | pubmed:meshHeading | pubmed-meshheading:15087031... | lld:pubmed |
| pubmed-article:15087031 | pubmed:meshHeading | pubmed-meshheading:15087031... | lld:pubmed |
| pubmed-article:15087031 | pubmed:meshHeading | pubmed-meshheading:15087031... | lld:pubmed |
| pubmed-article:15087031 | pubmed:meshHeading | pubmed-meshheading:15087031... | lld:pubmed |
| pubmed-article:15087031 | pubmed:meshHeading | pubmed-meshheading:15087031... | lld:pubmed |
| pubmed-article:15087031 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15087031 | pubmed:articleTitle | [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia]. | lld:pubmed |
| pubmed-article:15087031 | pubmed:affiliation | Department of Hematology, Nanfang Hospital, The First Military Medical University, Guangzhou, Guangdong, 510515, PR China. zhangm@fimmu.com | lld:pubmed |
| pubmed-article:15087031 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15087031 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:15087031 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
